Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Validation of the "ExSpiron©" in Patients With ALS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04089696
Recruitment Status : Not yet recruiting
First Posted : September 13, 2019
Last Update Posted : September 25, 2019
Sponsor:
Information provided by (Responsible Party):
Peter Wijkstra, University Medical Center Groningen

Brief Summary:

Non-invasive ventilation (NIV) in patients diagnosed with amyotrophic lateral sclerosis (ALS) is nowadays common practice to provide comfort at the end stage of the disease. As complaints vary there is the need of a non-invasive device to measure respiratory volume to objectify complaints.

The ExSpiron© is a device for non-invasive monitoring of respiratory volume. The validation of this monitor in patients with ALS is the aim of this study.

The hypothesis is that the ExSpiron© delivers a valid assessment of respiratory volume in patients with ALS


Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Neuromuscular Diseases Device: ExSprion Not Applicable

Detailed Description:

Rationale: Non-invasive ventilation (NIV) in patients diagnosed with amyotrophic lateral sclerosis (ALS) is nowadays common practice to provide comfort at the end stage of the disease. As complaints vary there is the need of a non-invasive device to measure respiratory volume to objectify complaints.

The ExSpiron© is a device for non-invasive monitoring of respiratory volume. The validation of this monitor in patients with ALS is the aim of this study.

The hypothesis is that the ExSpiron© delivers a valid assessment of respiratory volume in patients with ALS Objective: The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.

Study design: This is an intervention study The validation of the ExSpiron© in patients diagnosed with ALS is done during admission on the Respiratory Care Unit (RCU) of the University Medical Center Groningen (UMCG). At daytime, tidal volume (TV) and minute volume (MV) will be measured during spontaneous breathing with the ExSpiron© simultaneously with a pneumotachometer (gold-standard). After installation of the chest pad of the ExSpiron© and the pneumotachometer, the first measurements are in sitting position. Three complete cycles of ten breaths; normal breathing, slow-deep breathing and rapid-shallow breathing, will be done. Between each cycle, a pause is allowed. After completing this breathing sequence, it is repeated in supine position. If patients are not able to perform this in supine position, because of orthopnea, an angle of 45º degree is adequate. After completing this cycle, the chest pad should be left in place and the electromyography (EMG) equipment should be installed. During the first night of admission, a full night of measurement of TV and MV will be conducted using the ExSpiron©.

Study population: 10 patients diagnosed with ALS and an indication to start NIV, >18 years of age.

Intervention (if applicable): The ExSpiron© is a device for non-invasive monitoring of tidal volumes and minute ventilation in non-intubated patients by using a disposable chest pad.

Main study parameters/endpoints: The main endpoint is the validation of the ExSpiron© in patients diagnosed with ALS and screened positive for starting NIV.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: NIV has no known serious side effects. ALS patients differ in starting NIV is done on the RCU while patients are monitored as standard care, the ExSpiron© is not an extra risk complaints but those screened positive to start NIV are not associated with risks. The intervention product, ExSpiron© is a non-invasive monitor with a chest pad attached to the patient.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Intervention study
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Validation of the "Exspiron©" in Patients With Amyotrophic Lateral Sclerosis; Non-invasive Monitoring of Respiratory Volume.
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : September 2020


Arm Intervention/treatment
Experimental: ExSpiron
10 patients with ALS
Device: ExSprion
The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.




Primary Outcome Measures :
  1. The validity of the respiratory volumes (tidal volume and minute volume), compared tot the pneumotachometer. [ Time Frame: 1 year ]
    The validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.


Secondary Outcome Measures :
  1. The BORG RPE score (Ratings of Percieved Exertion) [ Time Frame: 1 year ]
    Visual analogue scale (VAS) score from 0-10, 0 is worse outcome, 10 is best outcome

  2. The Amyotrophic lateral Sclerosis Assessment Questionnaire (ALSAQ-40) [ Time Frame: 1 year ]
    questionaire, score 0-4; 0 is never and 4 is alway or can not do.

  3. SenTec is the name of a transcutaneous monitor [ Time Frame: 1 year ]
    Gas exchange during the night with the transcutaneous monitor SenTec©

  4. The EMG [ Time Frame: 1 year ]
    Respiratory muscle activity and patient-ventilator asynchrony during the night and during NIV assessed with surface electromyograph



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  • Participants diagnosed with ALS requiring NIV
  • Age > 18 of age; < 85 years of age
  • An indication to start chronic NIV, hypercapnic respiratory failure (arterial carbon dioxide PaCO2 > 6.0 kilo pascal (kPa) measured during daytime) or orthopnoea due to diaphragm paralysis.
  • Participants are able to provide feedback
  • Participants that are willing to participate and are able to consent and sign the informed consent form.

Exclusion Criteria:

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Clinically unstable
  • Acute respiratory failure
  • Participants with refractory hypotension, defined as systolic blood pressure less than 90 mmHg, despite inotropic agents
  • Uncontrolled cardiac ischemia or arrhythmias
  • Participants suffering from metastatic or terminal cancer
  • Other comorbid disease affecting respiration (ie obstructive sleep apnea, chronic obstructive pulmonary disease)
  • Participants lacking functional medical decision-making

Layout table for additonal information
Responsible Party: Peter Wijkstra, Principal Investigator P.J. Wijkstra, University Medical Center Groningen
ClinicalTrials.gov Identifier: NCT04089696     History of Changes
Other Study ID Numbers: UMCG
First Posted: September 13, 2019    Key Record Dates
Last Update Posted: September 25, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Peter Wijkstra, University Medical Center Groningen:
ALS
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Sclerosis
Neuromuscular Diseases
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases